Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) has issued its 2025 annual circular ahead of the 2 June 2026 AGM, detailing full-year results, capital allocation plans and upcoming shareholder resolutions.

Financial highlights • Revenue rose 3.70 % to RMB6.83 billion, driven by clinical-trial related and laboratory services (+4.57 %). • Net profit attributable to shareholders fell to RMB887.90 million. • Operating cash inflow reached RMB1.12 billion; year-end cash and cash equivalents stood at RMB1.72 billion. • Total assets amounted to RMB28.36 billion, with equity of RMB24.26 billion and liabilities of RMB4.10 billion.

Capital return & share repurchase • Board proposes a cash dividend of RMB1.26 (tax-inclusive) for every 10 shares, totalling RMB107.75 million. • During 1 Jan–30 Apr 2025 the company repurchased 6.15 million A-shares for RMB308.97 million. • Combined payout (dividend plus completed buy-backs) represents 46.93 % of 2025 attributable net profit. • Shareholders will also vote on a fresh mandate allowing on-market repurchase of up to 10 % of outstanding H-shares and issuance of up to 20 % new H-shares.

Balance-sheet flexibility • Management seeks approval to secure an integrated bank credit facility of up to RMB10 billion to support 2026 liquidity needs. • The board requests authority to amend the articles of association to create vice chairman and co-president roles.

Governance & elections • Re-election of founders Dr. Ye Xiaoping (Chairman), Ms. Cao Xiaochun (General Manager) and Mr. Wen Zengyu (COO) as executive directors. • Re-election of independent directors Mr. Yuan Huagang and Ms. Liu Yuwen, and proposed appointment of Mr. Paul Siu as a new independent director. • Independent directors will each receive annual remuneration of RMB300,000; executive directors draw remuneration from management roles only. • BDO China Shu Lun Pan is nominated to continue as external auditor for 2026.

Key meeting details • AGM and H-share class meeting: 10:00 a.m., 2 June 2026, Company headquarters, Hangzhou. Shareholders on register by 2 June 2026 are eligible to vote. • Voting will be by poll; cumulative voting applies to director elections.